Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies

British Journal of Cancer

Volumn 94, Issue 1, 2006, Pages 85-92

  Laux, I ^a   Jain, A ^a   Singh, S ^b   Agus, D B ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

EGFR; Gefitinib; HER2; Keratinocytes; Pertuzumab; Skin rash

Indexed keywords

ANTIBODY; CETUXIMAB; DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; HOMODIMER; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; PERTUZUMAB; PHOSPHOTRANSFERASE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; DRUG TARGETING; EPIDERMIS CELL; HUMAN; HUMAN TISSUE; KERATINOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN CULTURE; SKIN DISEASE; SKIN TOXICITY; SOLID TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL CULTURE TECHNIQUES; DIMERIZATION; EXANTHEMA; HUMANS; KERATINOCYTES; LIGANDS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 30644463008     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602875     Document Type: Article

References (46)

1. Agus D, Sweeney C, Morris M, Mendelson D, McNeel D, Ahmann F, Wang J, Derynck M, Kattan M, Scher H (2005a) Efficacy and Safety of Single Agent Omnitarg, a HER Dimerization Inhibitor, in Hormone Refractory Prostate Cancer after Failure of Taxane-based Therapy. Proc Am Soc Clin Oncol 23: 408
2. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137
3. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005b) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23: 2534-2543
4. Albanell J, Rojo F, Baselga J (2001) Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839. Semin Oncol 28: 56-66
5. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J (2002) Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124
6. Arteaga C (2003) Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 30: 3-14
7. Baselga J (2003) Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 9: 2389-2390
8. Burris III HA (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl 3): 10-15
9. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144: 1169-1176
10. Chan-Hui PY, Stephens K, Warnock RA, Singh S (2004) Applications of eTag trade mark assay platform to systems biology approaches in molecular oncology and toxicology studies. Clin Immunol 111: 162-174
11. Clark G, Perez-Soler R, Siu L, Gordon A, Santabarbara P (2003) Rash severity is predictive of increased survival with erlotinib HCl. Proc Am Soc Clin Oncol 22: 196
12. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE (2003) Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21: 1980-1987
13. De Potter IY, Poumay Y, Squillace KA, Pittelkow MR (2001) Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp Cell Res 271: 315-328
14. Dua R, Shi Y, Mukherjee A, Pidaparthi S, Kirakossian H, Cao L, Tan Y, Jarvis L, Gangakhedkar S, Pannu H, Chenna A, Nguyen T, Wallweber J, Tahir H, Singh S (2004) Development of Proximity based assay to detect and quantify erbB (or HER) receptor dimerization in formalin fixed-paraffin embedded tissue sections. Proc AACR-NCI-EORTC (abstract #083879)
15. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246
16. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 16: 1647-1655
17. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D (2003) Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 278: 23343-23351
18. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S., Rowinsky EK (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19: 3267-3279
19. Jost M, Kari C, Rodeck U (2000) The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 10: 505-510
20. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 290: 2149-2158
21. Li B, Chang CM, Yuan M, McKenna WG, Shu HK (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63: 7443-7450
22. Malik SN, Siu LL, Rowinsky EK, deGraffenried L, Hammond LA, Rizzo J, Bacus S, Brattain MG, Kreisberg JI, Hidalgo M (2003) Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 9: 2478-2486
23. Marques MM, Martinez N, Rodriguez-Garcia I, Alonso A (1999) EGFR family-mediated signal transduction in the human keratinocyte cell line HaCaT. Exp Cell Res 252: 432-438
24. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19: 6550-6565
25. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8: 3-9
26. Mendoza N, Phillips GL, Silva J, Schwall R, Wickramasinghe D (2002) Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62: 5485-5488
27. Miller JP (2002) Meeting today's analytical demands of system biology. Anal Res Technol 2: 16-17
28. Perez-Soler R (2003) Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology (Huntingt) 17: 23-28
29. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabarbara P, Bonomi P (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238-3247
30. Piepkorn M, Predd H, Underwood R, Cook P (2003) Proliferation- differentiation relationships in the expression of heparin-binding epidermal growth factor-related factors and erbB receptors by normal and psoriatic human keratinocytes. Arch Dermatol Res 295: 93-101
31. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, Jensen PJ (1997) EGF-R dependent regulation of keratinocyte survival. J Cell Sci 110(Pt 2): 113-121
32. Rowinsky EK (2003) Signal events: Cell signal transduction and its inhibition in cancer. Oncologist 8(Suppl 3): 5-17
33. Rowinsky EK, Schwartz GH, Gollob JA, Thompson JA, Vogelzang NJ, Figlin R, Bukowski R, Haas N, Lockbaum P, Li YP, Arends R, Foon KA, Schwab G, Dutcher J (2004) Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 22: 3003-3015
34. Salimi-Moosavi H, Jin X, Badal Y, Tian T, Pidaparthi S, Wei J, Samain C, Tahir H, Kirakossain H, Singh S (2004) Differential HER family receptor dimerization and downstream signaling in cancer cell lines. Proc AACR-NCI-EORTC (abstract #083876)
35. Saltz L, Kies M, Abbruzzese J, Azarnia N, Needle M (2003) The presence and intensity of the cetuximab-induced acne-like skin rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22: 204
36. Saltz LB, Meropol NJ, Loehrer Sr PJ, Needle MN, Kopit J, Mayer RJ (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201-1208
37. Shin D, Nemunaitis J, Zinner R, Donato N, Shin H, Myers J, Zhang P, Lenehan P, Hong WK (2001) A phase I clinical and biomarker study of CI-1033, a novel pan-erbB tyrosine kinase inhibitor in patients with solid tumors. Proc Am Soc Clin Oncol 20: 82
38. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL (2004) Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22: 77-85
39. Sramkoski RM, Pretlow II TG, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In vitro Cell Dev Biol Anim 35: 403-409
40. Stoll SW, Kansra S, Peshick S, Fry DW, Leopold WR, Wiesen JF, Sibilia M, Zhang T, Werb Z, Derynck R, Wagner EF, Elder JT (2001) Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes. Neoplasia 3: 339-350
41. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22: 3080-3090
42. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y (1996) A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16: 5276-5287
43. van Zandwijk N (2003) Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. Br J Cancer 89(Suppl 2): S9-S14
44. Vanhoefer U, Tewes M, Rojo F, Dirsch O, Schleucher N, Rosen O, Tillner J, Kovar A, Braun AH, Trarbach T, Seeber S, Harstrick A, Baselga J (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175-184
45. Xian W, Rosenberg MP, DiGiovanni J (1997) Activation of erbB2 and c-src in phorbol ester-treated mouse epidermis: possible role in mouse skin tumor promotion. Oncogene 14: 1435-1444
46. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137